Regeneron's George Yancopoulos spoke with Bloomberg at the JP Morgan healthcare conference about two major initiatives. The biotech firm is awaiting FDA feedback on its hearing loss gene therapy, a potential one-time treatment for genetic deafness. Separately, Regeneron is preparing to enter the crowded but lucrative market for weight loss drugs, aiming to challenge established players with its own metabolic therapies.

Gene therapy represents a high-stakes frontier for Regeneron, moving beyond its successful antibody platform. A successful hearing loss treatment would validate years of research and open a new revenue stream. Meanwhile, the push into obesity drugs reflects a strategic pivot to capture value in a market projected to exceed $100 billion annually, pressuring rivals like Novo Nordisk and Eli Lilly.

Investors are watching for specific FDA timelines on the gene therapy candidate, which could determine the company's near-term growth trajectory. Yancopoulos's comments also hinted at Regeneron's broader pipeline, which includes cancer and inflammatory disease treatments. The company's ability to execute on both novel gene therapy and established metabolic markets will be a key test of its innovative and commercial prowess.